Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow CAPRICOR THERAPEUTICS, INC.

Get SEC filing alerts via email and in your feed for CAPRICOR THERAPEUTICS, INC.

CAPR

CAPRICOR THERAPEUTICS, INC.

About CAPRICOR THERAPEUTICS, INC.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company developing cell and exosome-based therapies, primarily focusing on deramiocel, a cell therapy for Duchenne muscular dystrophy (DMD) cardiomyopathy. Its proprietary platforms target muscle degeneration and inflammation through immunomodulatory and regenerative mechanisms. Capricor’s business model centers on advancing clinical development, manufacturing, and partnering for commercialization in key markets including the U.S. and Japan.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from CAPRICOR THERAPEUTICS, INC.

1
1
CAPRICOR THERAPEUTICS, INC. Capricor Therapeutics Reports $33.9 Million Net Loss and Increased R&D Expenses for Q1 2026

Via official filing (AI summary) | 22 days ago | 0 comments

2
1
CAPRICOR THERAPEUTICS, INC. Capricor Therapeutics Reports Financial Results for 2025 with Increased Losses and R&D Spending

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
CAPRICOR THERAPEUTICS, INC. Capricor Therapeutics Reports No Revenue and Increased Losses in Latest Quarter

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
CAPRICOR THERAPEUTICS, INC. Capricor Therapeutics Reports Zero Revenue and Increased Losses in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
CAPRICOR THERAPEUTICS, INC. Capricor Therapeutics Reports $24.4 Million Net Loss and No Revenue in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
CAPRICOR THERAPEUTICS, INC. Capricor Therapeutics Reports Decline in Revenue and Increased Operating Losses in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments